Foreign-subsidy data is now a transaction workstream

A separate control now sits beside merger review

The European Union's Foreign Subsidies Regulation, or FSR, has applied since July 2023. It gives the European Commission tools to investigate whether financial support from non-EU governments distorts the internal market. The Commission describes the regime as closing a gap between EU State aid controls and previously unchecked subsidies granted by third countries [1]. For transactions, that means foreign-subsidy review is not simply another label for competition clearance. It is a distinct analysis with its own data set, thresholds, process and remedies.

A concentration is notifiable when at least one relevant business is established in the EU and generates at least EUR500 million of EU turnover, while the undertakings concerned have received more than EUR50 million in aggregate foreign financial contributions during the previous three years [2]. The term financial contribution is broader than a proven subsidy: it can cover grants, loans, guarantees, tax treatment, capital injections and public-sector purchases or supplies. The practical consequence is that teams must collect a wide population of contributions before they know which items may matter substantively.

The 2026 guidance makes evidence more useful, not less necessary

In January 2026 the Commission published final guidelines on how it applies important FSR concepts, including distortion, the balancing test and its power to call in below-threshold cases [3]. The guidance improves predictability, but it does not turn the assessment into a mechanical checklist. Current legal analysis highlights the distinction between support targeted at EU activity and non-targeted support that may still cross-subsidise EU operations [4]. It also notes that internal group policies alone may not be enough to demonstrate separation where funds can move across a corporate group.

Fact and inference should therefore remain separate. The fact is that the Commission can review notifiable concentrations and can also request notification of certain below-threshold deals before implementation [2][3]. Our inference is that a simple threshold memo prepared late in the timetable is no longer a sufficient operating control for groups with public-sector shareholders, state-backed finance, government contracts or material activity across several jurisdictions. The evidence needs to show who provided a contribution, which entity received it, its value and terms, and whether it could benefit the business being acquired or its EU activity.

Transaction design should absorb the information burden

The most useful response is to make FSR readiness part of transaction architecture. Sellers can maintain a rolling three-year contribution register aligned to the legal-entity perimeter. Buyers can identify potential state links and public financing during initial diligence, then test whether the target and bidder data can be reconciled. Deal teams should allocate responsibility for classification, create a controlled request list, and reserve enough time for missing records to be sourced from operating subsidiaries rather than reconstructed immediately before filing.

Transaction documents also need to reflect the real process. Conditions precedent, cooperation covenants, information-access rights and long-stop dates should account for FSR review separately from merger control and foreign-investment screening. Where exposure is uncertain, the timetable should identify a decision gate before signing or announcement. This is not an argument for stopping transactions involving public support. It is a case for sequencing evidence early enough that parties can assess the issue, price execution risk and negotiate an informed allocation of responsibilities.

• Map foreign financial contributions by legal entity, provider, jurisdiction, instrument, value and date.
• Reconcile the three-year data window across the buyer, target and any full-function joint venture perimeter.
• Treat gaps, estimates and unresolved attribution questions as explicit diligence items rather than silent assumptions.
• Keep FSR milestones separate from merger-control and foreign-investment approvals in the critical path.

Remedies and call-in risk affect execution choices

The Commission may close a case, accept commitments, prohibit a concentration, or issue a no-objection decision depending on its findings [2]. Published enforcement analysis indicates that commitments have included removing unlimited state guarantees, restricting financing flows and accepting other measures tailored to the identified distortion [4]. Those examples do not establish a universal remedy template. They do show that the source and mobility of financial support can affect both the review and the solution, which makes treasury, tax and ownership evidence relevant to transaction planning rather than a narrow filing exercise.

Remaining uncertainty is material. The facts of each contribution and corporate structure differ; guidance cannot eliminate judgement over benefit, attribution, distortion or the likelihood of a call-in. Enforcement practice is still developing, and procedural experience will continue to shape market expectations. The controllable variable is readiness: a verified contribution register, a defensible perimeter and a documented escalation path give a deal team better options than a late search across subsidiaries after the timetable is already public.

The operating conclusion

Foreign-subsidy diligence should be treated as an execution workstream wherever an EU transaction touches state-linked capital, public guarantees, tax concessions or significant government commerce. The objective is not to label every contribution a distortion. It is to create reliable evidence soon enough for counsel and the transaction team to determine whether notification, further analysis or timetable protection is required. In cross-border M&A, that evidence discipline can preserve competitive tension, reduce avoidable delay and make regulatory risk allocation more credible.